S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Palo Alto Networks aims at cyber security leadership
3 Reasons the Capital One-Discover merger is a big deal
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Housing data weakens, but Toll Brothers stock is still a buy
Teladoc Health gaps down to support level after weak guidance
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Palo Alto Networks aims at cyber security leadership
3 Reasons the Capital One-Discover merger is a big deal
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Housing data weakens, but Toll Brothers stock is still a buy
Teladoc Health gaps down to support level after weak guidance
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Palo Alto Networks aims at cyber security leadership
3 Reasons the Capital One-Discover merger is a big deal
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Housing data weakens, but Toll Brothers stock is still a buy
Teladoc Health gaps down to support level after weak guidance
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Palo Alto Networks aims at cyber security leadership
3 Reasons the Capital One-Discover merger is a big deal
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
How major US stock indexes fared Wednesday, 2/21/2024
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Housing data weakens, but Toll Brothers stock is still a buy
Teladoc Health gaps down to support level after weak guidance

Aquestive Therapeutics (AQST) Short Interest Ratio & Short Volume

$2.51
-0.14 (-5.28%)
(As of 02/21/2024 ET)

Aquestive Therapeutics Short Interest Data

Current Short Volume
1,740,000 shares
Previous Short Volume
1,900,000 shares
Change Vs. Previous Month
-8.42%
Dollar Volume Sold Short
$4.16 million
Short Interest Ratio / Days to Cover
2.9
Last Record Date
January 31, 2024
Outstanding Shares
66,770,000 shares
Percentage of Shares Shorted
2.61%
Today's Trading Volume
1,158,178 shares
Average Trading Volume
567,704 shares
Today's Volume Vs. Average
204%
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook
Short Selling Aquestive Therapeutics ?

Sign up to receive the latest short interest report for Aquestive Therapeutics and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

AQST Short Interest Over Time

AQST Days to Cover Over Time

AQST Percentage of Float Shorted Over Time


Aquestive Therapeutics Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
1/31/20241,740,000 shares $4.16 million -8.4%N/A2.9 $2.39
1/15/20241,900,000 shares $5.00 million -7.3%N/A3.6 $2.63
12/31/20232,050,000 shares $4.14 million -1.0%N/A4.6 $2.02
12/15/20232,070,000 shares $4.14 million +10.1%N/A6.1 $2.00
11/30/20231,880,000 shares $4.23 million -2.1%N/A5.9 $2.25
11/15/20231,920,000 shares $3.05 million -1.5%N/A8.5 $1.59
10/31/20231,950,000 shares $3.06 million -2.0%N/A9.1 $1.57
10/15/20231,990,000 shares $3.06 million -2.0%N/A6.8 $1.54
9/30/20232,030,000 shares $3.11 million +9.7%N/A6.7 $1.53
9/15/20231,850,000 shares $3.00 million +1.7%N/A5.4 $1.62
8/31/20231,820,000 shares $2.98 million -7.1%N/A4.9 $1.64
8/15/20231,960,000 shares $3.63 million -4.4%N/A4.3 $1.85
7/31/20232,050,000 shares $4.49 million +6.2%N/A3.4 $2.19
7/15/20231,930,000 shares $3.01 million +11.6%N/A3.2 $1.56
6/30/20231,730,000 shares $2.85 million -21.7%N/A2.9 $1.65
6/15/20232,210,000 shares $4.77 million +13.3%N/A3.8 $2.16
5/31/20231,950,000 shares $4.50 million +1.6%N/A3.5 $2.31
5/15/20231,920,000 shares $4.13 million +4.4%N/A3.8 $2.15
4/30/20231,840,000 shares $2.47 million -1.6%N/A4.8 $1.34
4/15/20231,870,000 shares $2.37 million +1.1%N/A6.4 $1.27
3/31/20231,850,000 shares $2.11 million +1.1%N/A6.4 $1.14
3/15/20231,830,000 shares $1.33 million -9.9%N/A6.2 $0.73
2/28/20232,030,000 shares $1.59 million +5.7%N/A7.3 $0.78
2/15/20231,920,000 shares $1.42 million +3.8%N/A7.3 $0.74
1/31/20231,850,000 shares $1.65 million +13.5%N/A7.1 $0.89
1/15/20231,630,000 shares $1.61 million -6.3%N/A6 $0.99
12/30/20221,740,000 shares $1.57 million -6.0%N/A5.7 $0.90
12/15/20221,850,000 shares $1.67 million -19.9%N/A3.4 $0.90
11/30/20222,310,000 shares $2.14 million -4.9%N/A4.1 $0.93
11/15/20222,430,000 shares $2.55 million -7.3%N/A3.7 $1.05
10/31/20222,620,000 shares $2.28 million -0.8%N/A3 $0.87
10/15/20222,640,000 shares $2.48 million -2.2%N/A3 $0.94
9/30/20222,700,000 shares $3.16 million +134.8%N/A3.1 $1.17
9/15/20221,150,000 shares $1.48 million +17.4%N/A1.7 $1.29
8/31/2022979,200 shares $1.41 million -5.9%N/A1 $1.45
8/15/20221,040,000 shares $1.66 million -1.0%N/A1.1 $1.60
7/31/20221,050,000 shares $863,100.00 +14.1%N/A1.3 $0.82
7/15/2022920,000 shares $800,400.00 -12.4%N/A1.3 $0.87
6/30/20221,050,000 shares $671,790.00 -22.8%N/A1.4 $0.64
6/15/20221,360,000 shares $1.20 million -9.3%N/A2 $0.88













AQST Short Interest - Frequently Asked Questions

What is Aquestive Therapeutics' current short interest?

Short interest is the volume of Aquestive Therapeutics shares that have been sold short but have not yet been covered or closed out. As of January 31st, traders have sold 1,740,000 shares of AQST short. Learn More on Aquestive Therapeutics' current short interest.

What is a good short interest ratio for Aquestive Therapeutics?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. AQST shares currently have a short interest ratio of 3.0. Learn More on Aquestive Therapeutics's short interest ratio.

Which institutional investors are shorting Aquestive Therapeutics?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Aquestive Therapeutics: Citadel Advisors LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Is Aquestive Therapeutics' short interest increasing or decreasing?

Aquestive Therapeutics saw a decline in short interest in January. As of January 31st, there was short interest totaling 1,740,000 shares, a decline of 8.4% from the previous total of 1,900,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

How does Aquestive Therapeutics' short interest compare to its competitors?

Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Aquestive Therapeutics: FibroGen, Inc. (14.73%), Ventyx Biosciences, Inc. (10.93%), Alimera Sciences, Inc. (0.58%), Trevi Therapeutics, Inc. (2.16%), Inventiva S.A. (0.17%), Relmada Therapeutics, Inc. (5.35%), Theseus Pharmaceuticals, Inc. (2.63%), CorMedix Inc. (13.12%), PDS Biotechnology Co. (16.97%), Abeona Therapeutics Inc (3.34%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($4.48 billion), General Motors ($3.85 billion), Charter Communications, Inc. ($3.38 billion), Occidental Petroleum Co. ($3.00 billion), Super Micro Computer, Inc. ($2.66 billion), Tractor Supply ($2.37 billion), Coinbase Global, Inc. ($2.25 billion), Moderna, Inc. ($2.11 billion), Royal Caribbean Cruises Ltd. ($2.06 billion), and Floor & Decor Holdings, Inc. ($1.67 billion). View all of the most shorted stocks.

What does it mean to sell short Aquestive Therapeutics stock?

Short selling AQST is an investing strategy that aims to generate trading profit from Aquestive Therapeutics as its price is falling. AQST shares are trading down $0.14 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Aquestive Therapeutics?

A short squeeze for Aquestive Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of AQST, which in turn drives the price of the stock up even further.

How often is Aquestive Therapeutics' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including AQST, twice per month. The most recent reporting period available is January, 31 2024.



More Short Interest Resources from MarketBeat

This page (NASDAQ:AQST) was last updated on 2/22/2024 by MarketBeat.com Staff